October 2013 Innovation Grants results

We are pleased to announce the results of the most recent Innovation Grants competition to support unique and creative research ideas that will impact cancer. Below is a listing of newly awarded Canadian Cancer Society (CCS) Innovation Grants.

Out of a total of 214 grant applications, 46 Canadian Cancer Society Innovation Grants have been approved – a 21% success rate. All grants have been awarded to a maximum budget of $200,000 with a maximum 3 year term. The 46 grants total almost $9 million in funding over the terms of these grants. This number is substantially higher than anticipated due to the strength of the submissions in this round, as a result additional funds were allocated.

We are also very pleased that all grants are being funded to their full panel recommended amounts and that no administrative decrements are being applied.

Funds committed to this competition have been made possible by the significant efforts of Canadian Cancer Society volunteers and donors across the country.

Summaries of awarded grants

Please note:

Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
The start date for these grants is February 1, 2014.
Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.

Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Applicant Institution Title	Award
Abraham, Ninan University of British Columbia Therapeutic targeting of the IL-7Ra pathway in acute lymphoblastic leukemia	2014/2015 : $66,668 2015/2016 : $66,666 2016/2017 : $66,666
Bally, Marcel BC Cancer Agency (Vancouver) Lipid-based nanoparticulate formulations of copper complexed diethyl-dithiocarbamate used alone and in combination with temozolomide and/or Irinophore C to treat glioblastoma multiforma	2014/2015 : $100,000 2015/2016 : $100,000
Batada, Nizar Ontario Institute for Cancer Research DNA repair associated mutational signatures as biomarkers	2014/2015 : $98,650 2015/2016 : $100,000
Blank, Volker Lady Davis Institute Novel regulatory pathways controlling hematopoietic stem cell fate	2014/2015 : $100,000 2015/2016 : $91,810
Boutros, Paul Ontario Institute for Cancer Research Genomic characterization of Rb1+/+ retinoblastoma	2014/2015 : $100,000 2015/2016 : $100,000
Buckstein, Rena Sunnybrook Research Institute The screening for MDS mutations in the aging population for early detection of disease	2014/2015 : $94,650 2015/2016 : $97,590
Cypel, Marcelo The Toronto Hospital (General Division) - UHN Development of isolated lung perfusion for the treatment of cancer metastases to the lungs	2014/2015 : $100,000 2015/2016 : $96,830
Dedhar, Shoukat BC Cancer Agency (Vancouver) Identification and development of novel anti-cancer agents targeting centrosome clustering	2014/2015 : $93,112 2015/2016 : $93,112
Diorio, Caroline Laval University DNA methylation in normal breast tissue associated to risk of second contralateral breast cancer	2014/2015 : $100,000 2015/2016 : $99,896
Dirks, Peter Hospital for Sick Children Wnt signalling control of glioblastoma stem cell fate	2014/2015 : $99,715 2015/2016 : $98,563
Fradet, Vincent Laval University Phase II double-blind randomized controlled trial of concentrated omega-3 (mainly EPA) before prostatectomy evaluating the effects on prostate cancer proliferation, inflammation and quality of life.	2014/2015 : $32,600 2015/2016 : $97,145 2016/2017 : $70,250
Gallouzi, Imed McGill University Role of stress granules in preventing cancer-induced muscle wasting	2014/2015 : $98,537 2015/2016 : $98,537
Girardin, Stephen University of Toronto The role of NLRX1 in colorectal cancer and apoptosis	2014/2015 : $95,000 2015/2016 : $95,000
Gotay, Carolyn University of British Columbia Increasing healthy outcomes for prostate cancer survivors: an innovative cooking class intervention feasibility study	2014/2015 : $73,328 2015/2016 : $85,907
Harkness, Troy University of Saskatchewan Metformin and microarrays: an innovative approach to treating and monitoring drug resistant canine lymphoma	2014/2015 : $78,832 2015/2016 : $86,168
Jones, Russell McGill University Investigating the role of the immune system in the pathology of LKB1-mediated tumourigenesis	2014/2015 : $62,435 2015/2016 : $63,435 2016/2017 : $66,435
Jones, Steven BC Cancer Agency (Vancouver) Modulators of FBXL2 to induce degradation of oncogenes – an innovative therapeutic approach	2014/2015 : $97,620 2015/2016 : $97,620
Joshua, Anthony Ontario Cancer Institute/PMCC - UHN The utility and relevance of exome sequence analysis and circulating tumour DNA in assessing tumour heterogeneity in BRAF mutant melanoma	2014/2015 : $62,005 2015/2016 : $90,695 2016/2017 : $46,980
Kelley, Shana University of Toronto An integrated fluidic chip for exosome analysis	2014/2015 : $100,000 2015/2016 : $100,000
Kerbel, Robert Sunnybrook Research Institute A strategy for developing models of spontaneous bone metastasis in mice	2014/2015 : $89,000 2015/2016 : $89,000
Khokha, Rama Ontario Cancer Institute/PMCC - UHN Proteome analysis of the mammary epithelial hierarchy: normal and high-risk	2014/2015 : $94,900 2015/2016 : $94,900
Kramer, Desre Cancer Care Ontario From awareness to behavioural change (A2B): exploring the impact of heightened awareness of workplace exposures in Sarnia and Sudbury	2014/2015 : $97,768 2015/2016 : $99,065
Kung, Sam K.P. University of Manitoba A novel role of GM-CSF in evading immune surveillance of natural killer cells in breast cancer	2014/2015 : $67,239 2015/2016 : $68,315 2016/2017 : $64,329
Lam, Wan BC Cancer Research Centre Development of organ specific immunomodulators for the treatment of lung cancer	2014/2015 : $100,000 2015/2016 : $100,000
Mai, Sabine University of Manitoba Nuclear architecture in cancer	2014/2015 : $99,999 2015/2016 : $98,211
Makrigiannis, Andrew University of Ottawa Innate immunosurveillance of breast cancer	2014/2015 : $92,707 2015/2016 : $92,707
Mazroui, Rachid Laval University Role of heme-regulated kinase in chemoresistance	2014/2015 : $78,000 2015/2016 : $78,000
Muller, William McGill University Targeting canonical Wnt/ß-catenin signalling in ErbB2 mammary tumour progression	2014/2015 : $97,500 2015/2016 : $97,500
Nelson, Brad BC Cancer Agency (Victoria) How does the immune system contend with intratumoral heterogeneity?	2014/2015 : $97,938 2015/2016 : $100,000
Nitz, Mark University of Toronto Mass cytometry probes to evaluate tumour hypoxia	2014/2015 : $99,750 2015/2016 : $99,750
Park, Morag McGill University Gastric cancer, mechanisms for intervention	2014/2015 : $100,000 2015/2016 : $100,000
Pause, Arnim McGill University Investigation of tumour suppressive mechanism of ESCRT-dependent receptor degradation	2014/2015 : $100,000 2015/2016 : $100,000
Petrecca, Kevin McGill University Development of novel therapeutics to prevent brain cancer invasion	2014/2015 : $86,500 2015/2016 : $84,000
Prive, Gilbert Ontario Cancer Institute/PMCC - UHN The function of LZTR-1 in glioblastoma	2014/2015 : $61,667 2015/2016 : $63,255 2016/2017 : $64,831
Ruth, Thomas BC Cancer Research Centre Targeted alpha therapy with At-211	2014/2015 : $96,966 2015/2016 : $100,000
Sabiston, Catherine University of Toronto Connecting peers in motion: a dyadic lifestyle activity intervention for women diagnosed with cancer	2014/2015 : $96,201 2015/2016 : $71,536 2016/2017 : $23,668
Shah, Sohrab University of British Columbia Building a bridge from the cancer genome to the cancer clinic with visual analytics	2014/2015 : $99,663 2015/2016 : $100,000
Sinnett, Daniel Hopital Sainte-Justine Long noncoding RNAs deregulated in childhood acute lymphoblastic leukemia	2014/2015 : $99,678 2015/2016 : $99,499
Steidl, Christian BC Cancer Research Centre Detection of genomic rearrangements in archival lymphoma tissues using targeted capture sequencing	2014/2015 : $100,000 2015/2016 : $99,351
Tepass, Ulrich University of Toronto A new model to study the cell biology of epithelial to mesenchymal transition (EMT)	2014/2015 : $69,500 2015/2016 : $64,500 2016/2017 : $64,500
Thomson, Axel McGill University Mediators of stromal androgen response in prostate cancer as new therapeutic interventions	2014/2015 : $44,000 2015/2016 : $47,000 2016/2017 : $44,500
Trudel, Suzanne Ontario Cancer Institute/PMCC - UHN A companion study to a phase II clinical trial of sequential treatment with MEK followed by AKT inhibition for the treatment of relapsed multiple myeloma	2014/2015 : $70,573 2015/2016 : $70,573 2016/2017 : $58,573
Veillette, Andre IRCM - Institut de Recherches Cliniques de Montréal Mouse models to understand mechanisms of action and toxicity of elotuzumab, a new treatment for multiple myeloma	2014/2015 : $66,666 2015/2016 : $66,666 2016/2017 : $66,668
Watson, Peter BC Cancer Research Centre Inflammation and resistance to endocrine therapy in breast cancer	2014/2015 : $96,708 2015/2016 : $96,708
Weber, Michael The Research Institute of the McGill University Health Centre (RI-MUHC) Bone scaffolds as delivery systems for local and controlled release of anti-resorptive in bone metastasis treatment	2014/2015 : $99,745 2015/2016 : $99,965
Young, Edmond University of Toronto Accessible microfluidic technology for modeling breast cancer tumor microenvironments	2014/2015 : $83,800 2015/2016 : $58,100 2016/2017 : $58,100

Last modified on: December 2, 2019